We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
febit’s miRBase 14 Geniom-Biochip now with 58 Additional new Sequences Available for Cancer Research
Product News

febit’s miRBase 14 Geniom-Biochip now with 58 Additional new Sequences Available for Cancer Research

febit’s miRBase 14 Geniom-Biochip now with 58 Additional new Sequences Available for Cancer Research
Product News

febit’s miRBase 14 Geniom-Biochip now with 58 Additional new Sequences Available for Cancer Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "febit’s miRBase 14 Geniom-Biochip now with 58 Additional new Sequences Available for Cancer Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

febit has announced that an updated version of the company’s Geniom Biochip containing 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14 is now available for cancer research.

The 58 new miRNA sequences were found by deep sequencing in a miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. All 58 miRNAs have been validated using the ABI TaqMan miRNA qRT-PCR assay and are now available for further studies using febit’s microarray technology for miRNA-profiling.

Several studies investigating the role of miRNAs showed evidence for their influence in cell development processes. Recently, promising biomarkers for the future diagnosis and differentiation of lung cancer and multiple sclerosis have been published in BMC Cancer and PLoS ONE. The results demonstrated that miRNA biomarkers reliably distinguish between affected and healthy individuals by analyzing whole blood samples. Each miRNA is part of a meaningful pattern giving information about individual regulatory processes. Therefore each miRNA of the Geniom Biochip, from either miRBase 14 or the SOLID sequencing-studies, will be of high scientific impact and can be a potential biomarker candidate or therapeutically relevant molecules.

Peer Staehler, febit’s CSO, said: “After the recent publication of promising results in biomarker discovery febit now enhanced its pipeline with novel, well validated content. febit plans to develop miRNA and other disease-related biomarkers which will help to detect diseases at early stages, diagnose the disease progression and monitor the response to treatment. In our studies we used whole blood, which is a well established sample source in the diagnostic practice.”
Advertisement